Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Extralabel Drug Use in Animals
[Federal Register Volume 91, Number 224 (Monday, November 23, 2026)]
[Notices]
[Pages 75514-75515]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2026-23740]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2026-N-5829]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Extralabel Drug Use
in Animals
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Submit written comments (including recommendations) on the
collection of information by December 23, 2026.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be submitted to https://www.reginfo.gov/public/do/PRAMain. Find this particular information
collection by selecting ``Currently under Review--Open for Public
Comments'' or by using the search function. The OMB control number for
this information collection is 0910-0325. Also include the FDA docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Kelly Covington, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 240-402-5661,
[email protected].
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Extralabel Drug Use in Animals--21 CFR 530
OMB Control Number 0910-0325--Extension
This information collection supports Food and Drug Administration
(FDA, us or we) implementation of section 512 of the Federal Food, Drug
and Cosmetic Act (FD&C Act) (21 U.S.C. 360b), which governs new animal
drugs. Agency regulations in 21 CFR part 530, permit FDA, if we find
that there is a reasonable probability that the extralabel use of an
animal drug may present a risk to public health, to establish a safe
level for a residue from the extralabel use of the drug, and to require
the development of an analytical method for the detection of residues
above that established safe level. This requirement is codified at 21
CFR 530.22(b). Although to date, we have not established a safe level
for a residue from the extralabel use of any new animal drug and,
therefore, have not required the development of analytical methodology,
we believe that there may be instances when analytical methodology will
be required. We are, therefore, estimating the reporting burden based
on two methods being required annually. The requirement to establish an
analytical method may be fulfilled by any interested person. We believe
that the sponsor of the drug will be willing to develop the method in
most cases. Alternatively, FDA, the sponsor, and perhaps a third party
may cooperatively arrange for method development. The respondents may
be sponsors of new animal drugs, State, or Federal and/or State
Agencies, academia, or individuals.
In the Federal Register of June 18, 2026 (91 FR 36868), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
FDA estimates the burden of this collection of information as
follows:
[[Page 75515]]
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
21 CFR part; activity Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
--------------------------------------------------------------------------------------------------------------------------------------------------------
530.22(b); Submission(s) of analytical method...................... 2 1 2 4,160 8,320
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Based on a review of the information collection since our last
request for OMB approval, we have made no adjustments to our burden
estimate.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2026-23740 Filed 11-20-26; 8:45 am]
BILLING CODE 4164-01-P
공식 발표 ↔ 매체 보도
보도 없음
보도 없음
보도 없음